Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
Public ClinicalTrials.gov record NCT02159573. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri® (Natalizumab) to Tecfidera® (Dimethyl Fumarate)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate relapse activity, as measured by the proportion of participants relapsed at 12 months, in participants with relapsing-remitting multiple sclerosis (RRMS) who transition from Tysabri (BG00002) to Tecfidera (BG00012) in the real-world setting. The secondary objective is to further evaluate relapse activity, defined as annualized relapse rate (ARR), hospitalization and intravenous corticosteroid use, during the first year of Tecfidera treatment following transition from Tysabri treatment.
Study identification
- NCT ID
- NCT02159573
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 530 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2014 (Type not available)
- Primary completion
- Jan 2015 (Actual)
- Completion
- Jan 2015 (Actual)
- Last update posted
- Jun 7, 2016
2014 – 2015
United States locations
- U.S. sites
- 43
- U.S. states
- 27
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Cullman | Alabama | — | — |
| Research Site | Gilbert | Arizona | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | Aurora | Colorado | — | — |
| Research Site | Centennial | Colorado | — | — |
| Research Site | Washington D.C. | District of Columbia | — | — |
| Research Site | Jacksonville Beach | Florida | — | — |
| Research Site | Palm Bay | Florida | — | — |
| Research Site | Tampa | Florida | — | — |
| Research Site | Athens | Georgia | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Idaho Falls | Idaho | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Peoria | Illinois | — | — |
| Research Site | Baton Rouge | Louisiana | — | — |
| Research Site | Glen Burnie | Maryland | — | — |
| Research Site | Boston | Massachusetts | — | — |
| Research Site | Farmington Hills | Michigan | — | — |
| Research Site | Golden Valley | Minnesota | — | — |
| Research Site | Lincoln | Nebraska | — | — |
| Research Site | Teaneck | New Jersey | — | — |
| Research Site | Amherst | New York | — | — |
| Research Site | East Meadow | New York | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Raleigh | North Carolina | — | — |
| Research Site | Columbus | Ohio | — | — |
| Research Site | Gahanna | Ohio | — | — |
| Research Site | Uniontown | Ohio | — | — |
| Research Site | Oklahoma City | Oklahoma | — | — |
| Research Site | Portland | Oregon | — | — |
| Research Site | Altoona | Pennsylvania | — | — |
| Research Site | Pittsburgh | Pennsylvania | — | — |
| Research Site | Nashville | Tennessee | — | — |
| Research Site | Dallas | Texas | — | — |
| Research Site | Salt Lake City | Utah | — | — |
| Research Site | Newport News | Virginia | — | — |
| Research Site | Norfolk | Virginia | — | — |
| Research Site | Seattle | Washington | — | — |
| Research Site | Spokane | Washington | — | — |
| Research Site | Madison | Wisconsin | — | — |
| Research Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02159573, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2016 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02159573 live on ClinicalTrials.gov.